What is the new preferred term for treatment‑resistant depression (TRD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

New Preferred Terminology for Treatment-Resistant Depression

The emerging preferred term is "Difficult-to-Treat Depression" (DTD), though "Treatment-Resistant Depression" (TRD) remains more widely recognized in scientific literature and may be more practical for broader communication. 1

The Terminology Shift

The term DTD is gaining traction among clinical experts as a more nuanced alternative to TRD, particularly in recent consensus discussions 1. However, this represents an evolving preference rather than a complete replacement:

  • DTD is favored because it acknowledges the multifactorial nature of treatment failure, including issues beyond pharmacological resistance such as adherence problems, comorbidities, and psychosocial factors
  • TRD remains dominant in regulatory documents (FDA, EMA), clinical trials, and the broader scientific literature 2

Practical Considerations

When to Use Each Term:

Use DTD when:

  • Discussing clinical cases where treatment failure may involve adherence issues, psychiatric comorbidities (personality disorders, substance abuse), or inadequate treatment optimization
  • Emphasizing a broader conceptualization that includes modifiable factors beyond pure pharmacological resistance 1

Use TRD when:

  • Conducting or referencing clinical trials and research
  • Communicating with regulatory bodies or following standardized diagnostic criteria
  • Ensuring clarity with international audiences who may not be familiar with the DTD terminology 1

Important Caveats

The terminology debate reflects a deeper issue: stricter definitions of TRD identify patients with genuinely worse clinical outcomes and lower remission rates 3. Looser criteria risk overdiagnosis and overtreatment, potentially labeling patients with "difficult-to-manage" depression (due to comorbidities) as having true treatment resistance 3.

Regardless of terminology used, the 2022 Molecular Psychiatry consensus guidelines define TRD as requiring at least two failed antidepressant treatments with <25% improvement at adequate dose and duration (96% consensus) 2. This operational definition remains standard regardless of whether you call it TRD or DTD.

The choice of terminology should not distract from the critical task of properly assessing treatment adequacy, adherence, and comorbidities before labeling any patient as treatment-resistant.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.